MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

BSX · NYSE

Boston Scientific Corporation

Health Care · Medical/Dental Instruments

Reference price$46.06As of Jul 28, 2026
Market capitalization$68.46B
52-week range$42.20–$109.50
S&P 500 portfolio weight0.11%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$55.00+19.4% vs. reference
Average$68.68+49.1% vs. reference
High$89.00+93.2% vs. reference
20 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableJun 2026
Consensus EPS$0.837 estimates
Expected range$0.82–$0.84Low to high EPS
Dec 2026$3.35Street EPS consensus
Dec 2027$3.69Street EPS consensus
Dec 2028$4.06Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+19.9% YoY$20.07B$16.75B
Operating income$3.61B$2.6B
Net income$2.9B$1.85B
Operating cash flow$4.53B$3.44B
Capital expenditures($0.88B)($0.79B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

NASDAQ.com

Pre-Market Earnings Report for July 29, 2026 : PG, APH, VRT, GD, ADP, JCI, AON, BSX, CVE, ETR, ODFL, GRMN

RTTNews

Boston Scientific Restructuring To Trim Workforce

Zacks

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.